Dr. Minzhao Lin , Biochemistry, Lecturer at Dezhou University, China
Dr. Minzhao Lin is a dedicated biomedical researcher and currently serves as a Lecturer at Dezhou College, China. With a Ph.D. in Biology and Medicine from Sun Yat-sen University, he has established himself in the interdisciplinary fields of nanomedicine, cancer immunotherapy, and tumor microenvironment modulation. He has authored over 24 publications, with 7 as co-first or corresponding author, and actively contributed to national-level research projects focusing on advanced drug delivery systems. Skilled in nanocarrier design, cellular assays, animal modeling, and analytical techniques, Dr. Lin bridges materials science with biomedical innovation. As a project group administrator, he successfully oversaw key grant applications and cross-disciplinary collaborations. His research emphasizes innovation in cancer therapy using hierarchical and responsive nanoplatforms. Dr. Lin is passionate about translational medicine and continuously seeks to advance therapies that can impact clinical outcomes in oncology and beyond.
Professional Profile :
Google Scholar
Orcid
Scopus
Summary of Suitability for Award:
Dr. Minzhao Lin stands out as a strong candidate for the “Best Researcher Award” due to his outstanding interdisciplinary contributions to cancer nanomedicine and immunotherapy. With a Ph.D. from Sun Yat-sen University and over 24 peer-reviewed publications (7 as co-first/corresponding author), he has demonstrated deep expertise in designing stimuli-responsive nanocarriers, microneedle drug delivery systems, and immune-modulatory therapeutic platforms. His research addresses real-world biomedical challenges like tumor drug resistance and targeted delivery across the blood-brain barrier, which are of high clinical relevance. He has successfully co-led multiple nationally funded projects, managed high-level lab operations, and contributed to grant proposals, manuscript drafting, and final reporting—demonstrating leadership, innovation, and research management capabilities. His work is published in top-tier journals like Nature Communications, Biomaterials, and ACS Applied Materials & Interfaces—signaling international recognition and scholarly impact. Dr. Minzhao Lin exemplifies the criteria for the “Best Researcher Award”, given his innovative research, publication record, leadership in key national projects, and substantial contributions to translational cancer nanomedicine. His work is not only academically robust but also holds significant potential for clinical applications. He is highly deserving of this recognition.
🎓Education:
Minzhao Lin pursued his academic journey through prestigious Chinese institutions. He earned his Ph.D. in Biology and Medicine (2020–2024) from the College of Materials Science and Engineering at Sun Yat-sen University, Guangzhou, China. His doctoral work focused on hierarchical nanomedicine for cancer immunotherapy. Prior to that, he completed his M.Sc. in Plant Prevention and Biomaterials (2017–2020) at South China Agricultural University, where he built foundational expertise in biomaterials and pathogen defense. His undergraduate degree in Environmental Science (2013–2017), also from South China Agricultural University, was marked by outstanding academic performance, with a GPA of 4.15/5 and a rank of 5th out of 330 students. This diverse educational foundation in environmental science, biomaterials, and biomedicine has equipped Dr. Lin with a unique interdisciplinary perspective vital for innovation in nanomedicine and cancer research.
🏢Work Experience:
Dr. Minzhao Lin serves as a Lecturer at Dezhou College, where he engages in teaching and scientific research. During his doctoral studies at Sun Yat-sen University (2020–2024), he managed national research projects, coordinated multi-institutional collaborations, and played a central role in nanodrug development. As a Project Group Administrator, he handled proposal drafting, procurement, lab safety, and team management. His technical expertise encompasses synthesis of polymeric/lipid nanocarriers, in vitro/in vivo biological assessments, and advanced imaging and analysis. Dr. Lin has worked extensively on microneedle-based drug delivery systems for cancer immunotherapy and contributed significantly to the completion of NSFC and Guangzhou Municipal R&D projects. He has also published in high-impact journals and participated in project finalization and grant reporting. His scientific rigor and leadership skills make him a valuable contributor to biomedical innovation and higher education.
🏅Awards:
Dr. Minzhao Lin has earned significant recognition for his contributions to biomedical research, particularly in the fields of nanomedicine and cancer immunotherapy. His scholarly impact is reflected in his role as co-first or corresponding author on seven high-impact publications and as co-author on an additional 17 papers in prestigious journals such as Nature Communications, Biomaterials, ACS Applied Materials & Interfaces, and Advanced Science. As a key contributor to two nationally funded research projects under the National Natural Science Foundation of China (NSFC) and the Guangzhou Municipal Key R&D Program, Dr. Lin successfully led the technical development and final reporting phases. His leadership as project group administrator resulted in the successful completion and approval of multiple major research grants. Through his innovative work on nanocarrier systems and microneedle-based delivery platforms, Dr. Lin has built a reputation for scientific excellence and research innovation, earning him institutional and collaborative accolades in China’s biomedical research community.
🔬Research Focus:
Minzhao Lin’s research centers on the development of hierarchical targeted nanomedicine for cancer immunotherapy . His work bridges materials science and oncology, designing multifunctional polymeric and lipid-based carriers that can modulate the tumor microenvironment, overcome drug resistance, and improve immune response activation. Key themes include ROS regulation, co-delivery of therapeutics, metabolism reprogramming, and stimuli-responsive systems. He has also advanced microneedle platforms and flocculant-based delivery technologies for therapeutic and environmental applications. Dr. Lin’s goal is to achieve precise and efficient drug delivery, especially in hard-to-treat cancers such as triple-negative breast cancer and glioma, through multimodal strategies. His collaborative efforts in integrating imaging, immunomodulation, and nanocarrier design reflect a holistic approach to personalized medicine and translational research.
Publication Top Notes:
1.Title: Surgical tumor-derived photothermal nanovaccine for personalized cancer therapy and prevention
Citations: 73
2.Title: GSH‐Responsive metal–organic framework for intratumoral release of NO and IDO inhibitor to enhance antitumor immunotherapy
Citations: 64
3.Title: Nanodrug augmenting antitumor immunity for enhanced TNBC therapy via pyroptosis and cGAS-STING activation
Citations: 56
4.Title: Floatable magnetic aerogel based on alkaline residue used for the convenient removal of heavy metals from wastewater
Citations: 41
5.Title: Transparent floatable magnetic alginate sphere used as photocatalysts carrier for improving photocatalytic efficiency and recycling convenience.
Citations: 34
6.Title: Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Citations: 33
7.Title: Nanodrugs incorporating LDHA siRNA inhibit M2-like polarization of TAMs and amplify autophagy to assist oxaliplatin chemotherapy against colorectal cancer
Citations: 26
8.Title: Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer
Citations: 23
9.Title: Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation
Citations: 23
10.Title: Nanodrug simultaneously regulates stromal extracellular matrix and glucose metabolism for effective immunotherapy against orthotopic pancreatic cancer
Citations: 23